Ticker Details
Neurocrine Biosciences, Inc. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
IPO Date:	May 23, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$12.91B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.86 | 1.95%
Avg Daily Range (30 D):	$1.78 | 1.33%
Avg Daily Range (90 D):	$1.73 | 1.23%

Institutional Daily Volume
Avg Daily Volume:	.69M
Avg Daily Volume (30 D):	1M
Avg Daily Volume (90 D):	.9M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	45
Avg Trade Size (Sh.) (90 D):	43

Institutional Trades
Total Institutional Trades:	12,112
Avg Institutional Trade:	$3.95M
Avg Institutional Trade (30 D):	$10.86M
Avg Institutional Trade (90 D):	$10.47M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$9.27M
Avg Closing Trade (30 D):	$24.86M
Avg Closing Trade (90 D):	$21.98M
Avg Closing Volume:	98.93K

News

Feb 12, 2026 @ 7:38 PM Analysts Stay Bullish As Neurocrine Shares Tumble ... Source: Vandana Singh

Dec 23, 2025 @ 1:14 PM Clinical Miss For Neurocrine's Cerebral Palsy Drug... Source: Vandana Singh

Dec 4, 2025 @ 12:12 AM Acadia Stock Up 59% in a Year — Is a $51 Mi... Source: Jonathan Ponciano

Aug 8, 2025 @ 6:45 AM Nxera Pharma Operational Highlights and Consolidat... Source: Nxera Pharma

Aug 1, 2025 @ 4:15 AM Neurocrine (NBIX) Q2 Revenue Jumps 17% Source: Jesterai

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$4.81	$1.54	$4.81
Diluted EPS	$4.67	$1.48	$4.67
Revenue	$2.86B	$805.5M	$2.86B
Gross Profit	$2.81B	$787.9M	$2.81B
Net Income / Loss	$478.6M	$153.7M	$478.6M
Operating Income / Loss	$619.1M	$210.9M	$619.1M
Cost of Revenue	$52.1M	$17.6M	$52.1M
Net Cash Flow	$480M	$372.8M	$480M
PE Ratio	28.04